REDWOOD CITY, Calif., Nov. 6, 2009 (GLOBE NEWSWIRE) -- Threshold Pharmaceuticals, Inc. (Nasdaq:THLD) today announced clinical trial results related to Threshold's clinical stage hypoxia-activated prodrug, TH-302. The results... [read full story]
|
RELATED
|
|
STOCK MARKETING INC PRESENTS : (NASDAQ: EPIC - Cyberonics Announces Conference Call to Discuss Fiscal Year 2010 Second Quarter Financial Results HOUSTON, Nov 06, 2009 -- Wizzard Media (NYSE Amex: WZE), the world's leading...
REDWOOD CITY, Calif., Nov. 6, 2009 (GLOBE NEWSWIRE) -- News) today announced clinical trial results related to Threshold's clinical stage hypoxia-activated prodrug, TH-302. Today's presentation focused on a clinical trial, the...
REDWOOD CITY, Calif., Nov. 6, 2009 (GLOBE NEWSWIRE) -- Threshold Pharmaceuticals, Inc. (Nasdaq:THLD) today announced clinical trial results related to Threshold's clinical stage hypoxia-activated prodrug, TH-302. The results...
